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Background
Targeting CD28 costimulation with antagonist anti-CD28
antibodies has the potential to block effector T cells with-
out perturbation of the CTLA-4 and PDL-1-mediated
inhibitory signals important for the function of Treg cells,
which might favour tolerance induction.
Methods and results
Here we evaluated in a non-human primates this “Treg
sparing strategy” with FR104, a novel monovalent huma-
nized and pegylated Fab’ anti-CD28 antibody fragment.
PK/PD studies in monkeys revealed that FR104 presented
an elimination half-life of 8 days and 100% target satura-
tion over at least a month after a single iv injection of
5 mg/kg. FR104 was next evaluated in a baboon kidney
allograft model at the dose of 5 mg/kg at day 0, 4, 14 and
then every two-week until 3 months. Monotherapy mod-
estly but significantly prolonged allograft survival (MST:
18.5 days for monotherapy vs 6 days for untreated recipi-
ents). FR104 synergized with low doses tacrolimus (low-
Tac, trough: 5-10 ng/ml; MST >100 days for FR104/
lowTac vs. 15 days for lowTac alone) as well as with calci-
neurin-free regimens: therapeutic doses of MMF or rapa-
mycin (day 0-90) with 1 mg/kg of corticosteroids from day
0-14 (MST >100 days for FR104 + MMF/Rapa vs. 18/15
days for MMF/Rapa alone). Flow cytometry analyses indi-
cated that blood Treg cells of the natural and inducible
types were preserved in FR104/MMF or FR104/lowTAC
bitherapies and accumulated in FR104 monotherapy and
in FR104/Rapa bitherapy, whereas Treg cells were lowered
by MMF and lowTac monotherapies. Histology also
revealed that CTLA4+ and Foxp3+ T lymphocytes were
accumulated into the graft of FR104 treated recipients.
Conclusion
FR104 presented Treg sparing properties in kidney trans-
plantation and this was associated with prevention of graft
rejection in synergy with tacrolimus, MMF or rapamycin.
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